Rise Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Rise Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-485	Closed	-$276	–	1644
2025 Q1	$276	Buy	+485	New	+$479	﹤0.01%	1427

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Rise Advisors's TNYA Position: Q2 2025 in Review

Rise Advisors sold out of Tenaya Therapeutics (TNYA) in Q2 2025, closing a stake of 485 shares — an estimated $276 sold.

Rise Advisors first reported a position in TNYA in Q1 2025 and held it in 1 quarter. The position peaked at $276 in Q1 2025. 89 funds tracked by Wall St. Rank hold TNYA as of Q2 2025.

Rise Advisors reported no remaining Tenaya Therapeutics position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 485 Tenaya Therapeutics shares in Q2 2025, an estimated $276.
Rise Advisors first reported a position in Tenaya Therapeutics in Q1 2025 and held it in 1 quarter.
Rise Advisors's Tenaya Therapeutics position peaked at $276 in Q1 2025.
89 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.